List view / Grid view
29 July 2014 | By Johnson & Johnson
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1 The FDA also approved IMBRUVICA for CLL patients with del 17p,1 a genetic…
1 July 2014 | By Johnson & Johnson
Johnson & Johnson announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion...
25 June 2014 | By Johnson & Johnson
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute...
23 June 2014 | By Johnson & Johnson
Johnson & Johnson announced that its Board of Directors has appointed D. Scott Davis, Chief Executive Officer and Chairman of United Parcel Service, Inc. as a Director of Johnson & Johnson...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
15 April 2014 | By Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…
In this Process Analytical Technology (PAT) In-Depth Focus: Presenting a rational approach to QbD-based pharmaceutical development: A roller compaction case study, PAT for pharmaceutical spray drying, PAT Roundtable, Show Preview: IFPAC® 2014...
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
18 October 2013 | By Johnson & Johnson
Dr. McClellan has more than two decades of public service and academic research experience...
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
1 October 2013 | By Johnson & Johnson
“Everyone needs a complete eye exam because that’s how you are more likely to prevent blindness and eye disease..."
27 September 2013 | By Johnson & Johnson
Japan is the first country in the world where SOVRIAD™ is approved...
19 August 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline..
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
